RBC Capital Keeps Their Buy Rating on Damora Therapeutics (DMRA)
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Brian Abrahams maintained a Buy rating on Damora Therapeutics (DMRA) with a $40.00 price target. This follows LifeSci Capital's June 22 report, which also issued a Buy rating with a higher $45.00 target. Abrahams is noted as a 5-star analyst covering the Healthcare sector.
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Damora Therapeutics, with a price target of $40.00.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Abrahams is a 5-star analyst with an average return of 15.8% and a 56.11% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Definium Therapeutics, and Biogen.
In a report released on June 22, LifeSci Capital also maintained a Buy rating on the stock with a $45.00 price target.